Navigation Links
Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
Date:7/24/2013

erein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
4. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
5. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
6. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
7. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
8. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
9. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
10. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
11. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Celsion Corporation (NASDAQ: ... data from its ongoing open-label Phase 2 DIGNITY ... Cancer (RCWBC).  The trial is designed to enroll ... is evaluating ThermoDox in combination with mild hyperthermia. ... eligible for evaluation of efficacy.  Based on data ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
(Date:7/24/2014)... and VANCOUVER, British Columbia , ... OGXI ) announced today that the Company,s ... Thursday, August 7, 2014, and that the Company will ... p.m. ET that afternoon. Management will provide an overview ... general business update. To access the ...
Breaking Medicine Technology:Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 2Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2
... 26 Bristol-Myers Squibb,Company (NYSE: BMY ) ... in which treatment of antiviral-naive adult chronic hepatitis ... viral,load reduction than adefovir at 96 weeks -- ... viral load to undetectable,levels is a measure of ...
... ... C Clarification of Oncogenic Pathways Aids ... Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology Helps ... of the European,Association for the Study of the Liver (EASL), experts reported advances in,basic ...
Cached Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:7/24/2014)... The first-ever successful isolation and culture of ... been achieved by NFCR-supported scientist Daniel Haber, M.D., Ph.D., ... an important milestone on the road to individualized cancer ... for each patient. , “Tumors evolve in response ... genetic features that make them resistant to drugs. If ...
(Date:7/24/2014)... cancer involves exposing the patient or their tumor more ... X-rays. The radiation damages the cancer cells irreparably. Unfortunately, ... the skin over the site of the tumor, which ... and even skin cancer. As such finding ways to ... in the International Journal of Low Radiation, Faruck Lukmanul ...
(Date:7/24/2014)... Researchers have uncovered a way the malaria parasite ... at Washington University School of Medicine in St. ... including bacterial infections and tuberculosis. , The study ... , Many organisms, including the parasite that causes ... which play multiple roles in keeping organisms healthy, ...
(Date:7/24/2014)... July 24, 2014 July 22, ... in sealant and anesthesia reversal products to National ... help save young smiles. The donation of over ... Oraverse® was distributed to America’s ToothFairy Affiliate clinical ... vital oral health services. The America’s ToothFairy Affiliate ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Recently, Stwd.co.uk, a ... enriched its product line by adding many new designs of ... All outfits in the new collection come with big discounts. ... launching a special offer on all these fashionable items. They ... example, a pink V-neck strapless beading prom dress was previously ...
Breaking Medicine News(10 mins):Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... most people sidelined for long, study shows , FRIDAY, July ... full participation in sports or activity within six months of ... , U.S. researchers examined questionnaires filled out by 165 patients, ... performed by a single surgeon between July 1, 2004 and ...
... though, that screenings remain vital , THURSDAY, July 9 (HealthDay ... a screening mammogram is unlikely to ever cause a problem, ... overdiagnosis rate of 35 percent came from an examination of ... researchers and published online Thursday in BMJ . , ...
... (NYSE: WPI ), a leading specialty pharmaceutical company, ... quarter 2009 financial results on Wednesday, July 29, 2009 prior ... Company will also host a conference call and webcast at ... discuss its financial results and provide an update on the ...
... INDIANAPOLIS, July 10 Eli Lilly and Company ... this, its 35th year of support for the Indiana Black Expo (IBE) ... and a presence at the IN Shape Indiana Black ... stay healthy in these uncertain economic times. , , An example ...
... PALM CITY, Fla., July 10 Connectyx Technologies Holdings Group, ... Company is looking to establish itself as the market leader ... by Connectyx CEO, Ronn Schuman during yesterday,s Nationwide Teleconference. ... a goal to reach 1.2 million members by the end ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Shoulder Surgery Helps Athletes Get Back in the Game 2Health News:More Mammograms May Mean More 'Harmless' Cancers 2Health News:Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 3Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 2Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: